Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates | Seeking Alpha
Puma Biotechnology, Inc. 2020 Current Report 8-K
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology
Puma Biotechnology, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotechnology Surging
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology Announces New Updates And Changes In Breast Cancer Treatment
Jobs with Puma Biotechnology
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
